Skip to main content

Johnson & Johnson posts a 6-per-cent decline in third-quarter profit, as larger overhead and production costs and a one-time charge offset higher foreign sales.

The health care giant says profit was $3.2-billion, or $1.15 per share. That's down from $3.42-billion, or $1.23 per share, a year earlier.

Excluding a 9-cent charge for the pending acquisition of medical device maker Synthes Inc., profit would have been $3.4-billion, or $1.24 per share.

Story continues below advertisement

The maker of baby products and biologic drugs had revenue totalling $16-billion, up 7 per cent from a year ago.

Analysts polled by FactSet were expecting earnings per share of $1.21 and sales of $16.02-billion.

Sales in all J&J three divisions were down in the U.S.

Report an error
Comments are closed

We have closed comments on this story for legal reasons. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.